Mass Spectrometry

Application note: Enabling single-software multiple attribute methodology (MAM) for the assessment of biopharmaceutical product quality attributes

29 November 2018 | By Fan Zhang, Sean McCarthy, Zoe Zhang

Development and production of biopharmaceuticals is complex. Even minor impurities, or changes in attributes such as glycosylation or charge heterogeneity, can have a profound impact on the safety and efficacy of the final product. Traditionally, multiple analytical techniques have been required to assess the full range of biopharmaceutical product attributes.…

Algorithm to more effectively identify antibiotic compounds

3 October 2018 | By Drug Target Review

An international team of scientists has developed a candidate identification technique in the form of an algorithm that reduces the chances of rediscovering known compounds.

CT45 biomarker found in ovarian cancer can predict response to therapy

26 September 2018 | By Dr Zara Kassam (Drug Target Review)

New approach could prolong survival and trigger an immune...

Mass spectrometry and drug development – how the two come together

22 September 2018 | By Manfred Raida (National University of Singapore)

Since the development of the so-called soft ionisation techniques: electrospray ionisation and matrix-assisted laser desorption and ionisation in the 1980s and early 1990s and the development of high-resolution mass spectrometers, mass spectrometry (MS) has come to the fore in studying complex biological systems...

Eppendorf

D-PDMP reverses hair loss and skin damage linked to fatty diet

2 August 2018 | By Dr Zara Kassam (Drug Target Review)

In a series of experiments, researchers have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation...

Breath tests could detect pancreatic cancer

20 July 2018 | By Drug Target Review

Breath tests analysing organic compounds in exhaled breath could be used as a new diagnostic tool for pancreatic cancer...

New target for treating heart failure identified by Penn Medicine researchers

13 June 2018 | By Drug Target Review

Reversing modifications in diseased heart muscle cell struts called microtubules (MT) can lessen the stiffness and improve the beating strength of these cells isolated from transplant patients with heart failure.

Could fingerprints play a role in drug trials of the future? A forensic scientist’s perspective

25 May 2018 | By Melanie Bailey (University of Surrey)

Although readers of Drug Target Review may be more focused upstream of clinical trials in the drug discovery pipeline, the efficacy of clinical trials should also be of interest. Millions of pounds invested in drug discovery in the laboratory could easily go to waste if the clinical trials stage is…

13th International Conference on Metabolomics and Systems Biology

18 May 2018 | By Conference Series LLC

Euro Metabolomics 2018 will be a platform to investigate on recent research and advancements that can be useful to the researchers.

Charles River Laboratories expands services for early discovery screening

18 May 2018 | By Charles River Laboratories

Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.

Researchers uncover up to 100 potential drug targets for cancer

17 May 2018 | By Drug Target Review

In a new study based on mouse cells, researchers have identified several new potential targets using state-of-the-art technology, many of which could be employed for future treatment of different types of cancers and diseases.

ELRIG UK hosts inaugural Discovery Technologies event

8 May 2018 | By ELRIG

ELRIG (European Laboratory Research & Innovation Group) has announced its first Discovery Technologies meeting, which will take place at Alderley Park, located near Macclesfield in Cheshire.

New study discovers cancer-relevant protein shield

18 April 2018 | By Drug Target Review

Researchers have uncovered a new protein shield that aids in repairing damaged DNA in cells and affects resistance to drugs used for breast cancer treatment...

How the study of lipidomics is benefiting from recent advances in mass spectrometry

10 April 2018 | By Cristina Legido-Quigley (Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen)

There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.